Table 3.
Selected patient information
| Patient | Age (years)* | Site | Host variables relevant to staging | Host status† | Index to symptom onset interval (months) | Infection duration (days) | Isolate from preoperative aspiration and/or Stage I debridement | Isolate from Stage II debridement | IV Antibiotics during 6 weeks after débridement | Length of followup (months) | Duration off antibiotics at last followup (months) | Oral antibiotics at last followup | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 28 | TKA | Leukemia, h/o BMT, immunosuppressive drugs | II-B-1 | 5.0 | 1 | Cultures negative | Cultures negative | Ceftriaxone | 48.4 | 0 | PCN V | Controlled |
| 2 | 29 | TKA | h/o osteosarcoma | II-B-1 | 114.5 | 1 | Cultures negative | Cultures negative | Vancomycin, ceftriaxone | 25 | 16.6 | none | Controlled |
| 3 | 56 | THA | Synovial-cutaneous fistula, prior trauma | I-A-2 | 0.7 | 1 | MRSA | MRSA | Linezolid, PO rifampin | 83.8 | 62.9 | none | Controlled |
| 4 | 66 | THA | Alcoholism | II-B-1 | 132.2 | 2 | Cultures negative | No cultures taken | Cefazolin | 42.8 | 43.8 | none | Controlled |
| 5 | 76 | TKA | None | II-A-1 | 11.8 | 2 | Cultures negative | Cultures negative | Penicillin | 84.7 | 72.9 | none | Controlled |
| 6 | 71 | TKA | None | II-A-1 | 14.0 | 2 | MSSA | No cultures taken | Cefazolin, PO rifampin | 28.2 | 18.2 | none | Controlled |
| 7 | 61 | THA | None | II-A-1 | 124.9 | 2 | MSSA | Cultures negative | Ciprofloxacin, PO rifampin | 89.4 | 71.8 | none | Controlled |
| 8 | 72 | TKA | h/o lung cancer, multiple myeloma | II-C-1 | 5.8 | 3 | Streptococcus pneumoniae | Cultures negative | Ceftriaxone | 13.8 | 0 | TMP-SMX | Controlled |
| 9 | 77 | TKA | None | II-A-1 | 9.1 | 3 | Coagulase-negative Staphylococcus | Cultures negative | Cefazolin, PO rifampin | 23.5 | 0 | levofloxacin | Controlled |
| 10 | 80 | TKA | Age, h/o prostate cancer | II-B-1 | 208.0 | 3 | Escherichia coli | Cultures negative | Ceftriaxone | 28.3 | 0 | cephalexin | Controlled |
| 11 | 63 | TKA | Chronic lymphedema | II-A-2 | 55.3 | 3 | MSSA | Cultures negative | Nafcillin, PO rifampin | 22.9 | 0 | cephalexin | Controlled |
| 12 | 70 | TKA | None | II-A-1 | 4.2 | 4 | Group G β-hemolytic Streptococcus | Cultures negative | Ampicillin | 56.2 | 51 | none | Controlled |
| 13 | 85 | TKA | Age, alcoholism | I-B-1 | 0.9 | 4 | Peptostreptococcus and MRSA | Cultures negative | Vancomycin, PO rifampin | 46 | 43.1 | none | Controlled |
| 14 | 70 | TKA | DM II, h/o splenectomy | II-B-1 | 29.9 | 5 | MSSA | Cultures negative | Cefazolin, PO rifampin | 23.5 | 15.6 | none | Controlled |
| 15 | 78 | THA | Non-Hodgkin’s lymphoma, Sjogren’s syndrome, myelodysplasia | II-C-1 | 10.3 | 5 | Enterococcus faecalis | Cultures negative | Daptomycin | 14.5 | 0 | ampicillin | Controlled |
| 16 | 51 | TKA | h/o splenectomy, renal transplant, immunosuppressive drugs, | II-B-1 | 20.8 | 7 | Escherichia coli | Cultures negative | Ceftriaxone | 53.5 | 0 | TMP-SMX | Controlled |
| 17 | 68 | TKA | Non-Hodgkin’s lymphoma, metastatic renal cancer, h/o Merkel cell cancer | II-C-1 | 2.1 | 10 | Streptococcus pneumoniae | Cultures negative | Ceftriaxone, levofloxacin | 24.9 | 0 | TMP-SMX | Controlled |
| 18 | 73 | TKA | None | II-A-1 | 79.5 | 10 | Cultures negative | Cultures negative | Vancomycin | 50.1 | 48.7 | none | Controlled |
| 19 | 70 | TKA | DM II, h/o breast cancer | II-B-2 | 36.8 | 12 | Streptococcus agalactiae | No cultures taken | Ceftriaxone, gentamicin | – | – | PCN V | Failed |
| 20 | 91 | TKA | Age, rheumatoid arthritis, immunosuppressive drugs | II-C-2 | 252.3 | 16 | MRSA | MRSA | Vancomycin, PO rifampin | – | – | minocycline | Failed |
*Age at time of Stage I débridement; †as defined by McPherson et al. [22, 33]; h/o = history of; BMT = bone marrow transplant; DM II = Type II diabetes mellitus; MSSA = methicillin-sensitive Staphylococcus aureus; MRSA = methicillin-resistant Staphylococcus aureus; MRSE = methicillin-resistant Staphylococcus epidermidis; PO = oral. PCN = penicillin; TMP-SMX = Trimethoprim-Sulfamethoxazole; Infection duration = Symptom onset to débridement interval.